Attorney Advertising
EyePoint (EYPT) Securities Class Action: DURAVYU Trial Allegations and January 19, 2027 Lead Plaintiff Deadline
By W. Scott Holleman, Partner · Julie & Holleman LLP
Published November 19, 2026
A federal securities class action, Kälin v. EyePoint, Inc., alleges that EyePoint (NASDAQ: EYPT) and three senior officials presented an overly favorable picture of DURAVYU — its investigational sustained-release treatment for wet age-related macular degeneration — before its two pivotal Phase 3 trials, LUGANO and LUCIA, missed their primary endpoints in the full datasets. The proposed class period runs May 27, 2025 – August 14, 2026, with a lead-plaintiff deadline of January 19, 2027. The allegations have not been proven.
A federal securities class action has been filed against EyePoint, Inc. (NASDAQ: EYPT) and three of its senior officials over statements concerning DURAVYU — the company's investigational sustained-release treatment for retinal disease — and its prospects in pivotal Phase 3 clinical trials for wet age-related macular degeneration (wet AMD). The complaint alleges the company and its executives presented an overly favorable picture of DURAVYU's efficacy and resulting clinical, regulatory, and commercial prospects.
The case is Kälin v. EyePoint, Inc., et al., No. 1:26-cv-07418, in the U.S. District Court for the Eastern District of New York; the complaint is dated November 17, 2026. It names EyePoint, CEO Jay S. Duker, CFO George O. Elston, and Chief Medical Officer Ramiro Ribeiro, asserting claims under Section 10(b) and Section 20(a) of the Securities Exchange Act and SEC Rule 10b-5 — the core provisions of any securities class action.
The currently pleaded class period is May 27, 2025 through August 14, 2026, inclusive, and publicly issued notices identify January 19, 2027 as the deadline for an investor seeking appointment as lead plaintiff. The allegations remain unproven; filing a complaint does not establish that any defendant violated the law. Julie & Holleman LLP did not file this action and is not counsel of record or court-appointed lead counsel; the firm is independently reviewing the allegations and the rights of investors and continuing shareholders.
- Case Details
- Case
- Kälin v. EyePoint, Inc., et al.
- Court
- U.S. District Court, Eastern District of New York
- Case No.
- 1:26-cv-07418
- Class Period
- May 27, 2025 – August 14, 2026
- Lead Plaintiff Deadline
- January 19, 2027
What Does the EyePoint Complaint Allege?
According to the complaint, EyePoint emphasized the favorable profile of DURAVYU while advancing two pivotal Phase 3 studies, LUGANO and LUCIA, for wet AMD. The complaint identifies press releases, earnings calls, and regulatory filings between May 2025 and August 2026 that portrayed the product as clinically differentiated and potentially commercially significant, pointing to earlier Phase 2 findings, the proposed mechanism of action, the sustained-delivery approach, and the possibility of reducing the treatment burden faced by patients who need repeated injections.
The plaintiff alleges those statements were materially misleading because DURAVYU was less effective, and its prospects less secure, than investors had been led to believe — centering on what the defendants allegedly knew or recklessly disregarded when discussing clinical evidence before the pivotal readouts. The defendants' knowledge, the truth or falsity of particular statements when made, materiality, scienter, loss causation, and damages all remain issues for litigation.
It is not enough simply to observe that a drug candidate later failed to meet a clinical endpoint and conclude that prior optimism was fraudulent. The complaint makes a distinct securities-law allegation about the accuracy and completeness of statements made at the time, and whether the evidence supports that allegation has not been determined.
What Is DURAVYU, and What Were LUGANO and LUCIA Testing?
DURAVYU is EyePoint's investigational vorolanib intravitreal insert, designed for sustained drug delivery in the eye. The LUGANO and LUCIA trials evaluated DURAVYU in people with active wet AMD, a retinal condition that can cause central vision loss. Both were randomized, double-masked, aflibercept-controlled, non-inferiority Phase 3 studies, with a primary endpoint involving the mean change in best-corrected visual acuity (BCVA) from baseline at Weeks 52 and 56 compared with the control group. The complaint identifies enrollment of 432 patients in LUGANO and 475 in LUCIA.
A non-inferiority trial tests whether an investigational treatment is not unacceptably worse than an active comparator under a prespecified statistical framework. Missing the primary non-inferiority endpoint is not the same as establishing that the investigational treatment has no efficacy, and any interpretation should account for both the primary and secondary data, the trial's analysis plan, and the limits of any additional exploratory analysis.
Why Did the August 17, 2026 LUGANO Announcement Matter?
On August 17, 2026, EyePoint announced that the LUGANO Phase 3 trial did not achieve its primary endpoint in the full analysis dataset. The company attributed part of the result to an unevenly distributed group of patients who experienced significant vision loss from causes other than wet AMD, and reported that an ad hoc analysis excluding nine such patients from the DURAVYU group produced a non-inferiority finding. That exploratory result did not change the fact that the prespecified primary endpoint was missed in the full dataset.
EyePoint also reported positive findings on secondary measures, including a 42% reduction in treatment burden versus on-label aflibercept through Week 56, with favorable safety and anatomic observations. These are part of the company's reported trial results and should not be omitted — but successful secondary measures do not erase the prespecified primary-endpoint outcome.
The complaint alleges EyePoint's stock fell $9.88 per share, or approximately 66.98%, to a $4.87 closing price on August 17, 2026, and treats that announcement as the principal corrective disclosure for the currently pleaded class. Those stock-price figures are stated as allegations in the complaint and do not represent a judicial finding that all of the market decline was attributable to securities fraud.
What Happened in the Second Phase 3 Trial, LUCIA?
On October 19, 2026, EyePoint announced that LUCIA also missed its primary non-inferiority endpoint in the full analysis population, notwithstanding visual improvement and reported secondary benefits — including a 38% reduction in treatment burden, additional supplement-free outcomes, and a favorable safety profile. The company continued to emphasize additional data analyses and the therapeutic rationale for DURAVYU in other retinal indications.
The complaint alleges EyePoint shares declined another $2.55, or approximately 85.28%, closing at $0.44 on October 19. Importantly, October 19 is after the currently pleaded class period, which ends August 14, 2026 — it is discussed in the complaint as a later development, not as a basis to silently enlarge the proposed class period. The characterization and legal significance of these later disclosures will depend on the litigation.
What Has EyePoint Said Since the Trial Readouts?
In its November 12, 2026 third-quarter business update, EyePoint confirmed that the full-population primary endpoints were not achieved in either wet AMD study, and described a shift in resources toward its separate diabetic macular edema (DME) development program, including the Phase 3 COMO and CAPRI studies. The company stated those trials were fully enrolled and that it expected topline data in early fourth-quarter 2027 — a company expectation, not a guaranteed event, and not a prediction of FDA approval.
EyePoint also reported a workforce reduction of approximately 53% tied to its strategic prioritization, with anticipated annualized savings of about $30 million, and cited roughly $118 million in cash, cash equivalents, and short-term investments as of September 30, 2026. These corporate updates provide important context; by themselves they do not establish scienter, a disclosure violation, or a viable derivative claim.
Does the Complaint Address the October 2025 Financing or Executive Stock Sales?
Yes. The complaint refers to an October 2025 public offering involving common stock and pre-funded warrants and alleges that several executives sold shares during the proposed class period. These allegations form part of the plaintiff's scienter theory.
They are not independent findings of insider trading, and the existence of corporate fundraising or insider sales, without further facts, does not itself prove a securities violation. The complaint presently pleads Exchange Act claims; it should not be described as an already-filed Section 11 Securities Act offering case.
What Federal Securities Claims Have Been Asserted?
The complaint asserts Section 10(b) and SEC Rule 10b-5 claims relating to allegedly false or misleading statements and omissions, together with Section 20(a) claims directed at alleged controlling persons.
These claims require more than evidence that a stock price declined or a product failed to meet expectations. Questions of materiality, state of mind, reliance, causation, damages, and available defenses all remain open, and there is no judicial finding that EyePoint or any executive violated the federal securities laws.
Who Is Included in the Proposed EYPT Class Period?
The November 17 complaint seeks to represent persons and entities other than defendants who purchased or otherwise acquired EyePoint securities between May 27, 2025 and August 14, 2026, inclusive, and were damaged as alleged. This is a proposed, not yet finally certified, class definition, and it can change during the litigation. Investors should preserve account statements, confirmations, transaction histories, corporate-action records, and records of securities acquired or sold.
A purchase solely on August 17 or October 19 falls outside the complaint's currently pleaded period, although an investor's overall circumstances may call for individualized review. The proposed class refers to EyePoint securities; whether particular instruments and transactions fall within the actionable class and damages framework should not be assumed merely from a ticker search.
What Is the January 19, 2027 Lead Plaintiff Deadline?
Published notices identify January 19, 2027 as the deadline to ask the court to appoint a lead plaintiff under the Private Securities Litigation Reform Act (PSLRA). A lead plaintiff is an investor or investor group appointed to represent the proposed class and supervise the litigation and selection of class counsel, subject to the court's determination.
Do I Have to Move by the Deadline?
The deadline is not ordinarily a requirement that every affected investor file a motion just to remain a passive class member in a class that may later be certified. A settlement or judgment, if one occurs, may involve different notices and proof-of-claim procedures.
Should I Confirm the Current Status?
The lead-plaintiff deadline is subject to applicable notice and court orders, so interested investors should not rely on a static webpage without confirming current docket information. No firm can promise that an investor will be selected or that a recovery will result.
What About Investors Who Owned EYPT Before May 27, 2025 and Still Own It?
The securities complaint centers on alleged trading losses of investors who acquired securities within the proposed period. Different questions may arise for continuing stockholders who held shares before some of the alleged conduct and still hold shares. EyePoint is incorporated in Delaware, where — depending on the facts and relevant standing requirements — a stockholder may explore whether misconduct caused injury to the corporation itself rather than merely losses on personal trades.
Julie & Holleman LLP is separately evaluating whether a books-and-records investigation or potential stockholder-derivative claims may be warranted regarding the clinical disclosures, the company's information and oversight processes, and any resulting corporate injury. The securities complaint does not establish that officers or directors breached fiduciary duties, that corporate harm occurred, or that any derivative claim can be maintained. In particular, Delaware derivative standing, demand or demand futility, and the contemporaneous and continuous ownership requirements all require separate analysis — pre-class-period ownership alone is not sufficient.
Julie & Holleman LLP Is Reviewing EyePoint Investor and Shareholder Rights
Julie & Holleman LLP is reviewing the federal securities complaint regarding EyePoint, DURAVYU, the LUGANO and LUCIA Phase 3 programs, and related corporate disclosures. We welcome inquiries from two groups, and some investors may fall into both:
Investors With Securities Losses
Investors who purchased or acquired EyePoint securities during May 27, 2025 – August 14, 2026, particularly those considering the January 19, 2027 lead-plaintiff process.
Continuing EyePoint Shareholders
Continuing EyePoint shareholders interested in a separate, preliminary evaluation of potential Delaware corporate-governance or derivative claims, which involve different legal requirements and are assessed separately.
Frequently Asked Questions About EyePoint (EYPT)
- What is the EyePoint securities lawsuit?
- Kälin v. EyePoint, Inc., et al. is a federal securities class action alleging misleading statements or omissions about DURAVYU's efficacy and wet AMD development prospects. The allegations are unproven, and Julie & Holleman LLP is not counsel of record.
- What is the EYPT class period?
- May 27, 2025 through August 14, 2026, inclusive, as currently pleaded.
- When is the EyePoint lead plaintiff deadline?
- Published notices identify January 19, 2027, subject to further docket developments.
- What was the principal LUGANO result?
- EyePoint reported that the prespecified primary non-inferiority endpoint was not met in the full dataset. It also reported favorable secondary endpoints and a positive ad hoc analysis that excluded an asymmetric nine-patient cohort — an exploratory analysis that did not change the missed primary endpoint.
- Did LUCIA meet its primary endpoint?
- No. EyePoint reported on October 19, 2026 that LUCIA also missed the primary non-inferiority endpoint in the full analysis population, while reporting some positive secondary observations.
- Was October 19 inside the class period?
- No. October 19 is a subsequent development discussed in the complaint. The currently pleaded class period ends August 14, 2026.
- Did missing a non-inferiority endpoint mean DURAVYU does not work?
- No. Missing a prespecified primary non-inferiority endpoint in the full dataset is not the same as establishing that the treatment has no efficacy, and EyePoint also reported favorable secondary results.
- Did the FDA reject or disapprove DURAVYU because of this lawsuit?
- The complaint does not establish that. Clinical-trial endpoints and regulatory determinations are distinct issues; do not infer an FDA decision from a missed endpoint.
- Do I have to become lead plaintiff to be part of the class?
- Generally, no. Lead-plaintiff appointment is different from passive class membership, subject to certification and later orders.
- What if I held EyePoint before May 27, 2025?
- Earlier ownership may matter to a separate evaluation of potential Delaware derivative rights, especially where the investor continued holding through the relevant conduct. No derivative claim is established by the securities complaint alone.
- Has any defendant been found liable?
- No. No such finding is established by this complaint; its allegations are contested litigation claims, not adjudicated facts.
Related guides
Contact
W. Scott Holleman, Partner
Julie & Holleman LLP
Scott focuses his practice on stockholder litigation involving federal securities laws, corporate governance, mergers and acquisitions, and other public-company disputes.
Prior results do not guarantee a similar outcome.
Disclaimer: This page discusses allegations in a newly filed, contested complaint and public corporate disclosures, attributed to the complaint or to EyePoint as applicable; the August 17 (LUGANO), October 19 (LUCIA), and November 12 (Q3) disclosures are identified by date, and October 19 and November 12 are after the pleaded class period. EyePoint reported that its Phase 3 trials missed their prespecified primary non-inferiority endpoints in the full datasets while also reporting favorable secondary results; nothing here states that DURAVYU is ineffective or that any FDA decision has been made. The securities action was brought by other counsel; Julie & Holleman LLP is not counsel of record or lead counsel. No liability, insider trading, or derivative claim is established. This page is general information, not legal advice.
